Suven Life Sciences completes Phase 2 POC for Alzheimer drug
Suven Life Sciences Limited has informed the bourses that the last patient has completed his last visit for the Phase 2 POC study of SUVN-502 for moderate Alzheimer’s disease. This is the first-ever study to evaluate a triple combination therapy for moderate Alzheimer’s disease patients.
The study duration is of 30 weeks. There is an urgent need for treatment options for patients with Alzheimer’s disease (AD) dementia since there are no new drugs discovered or developed since 2003. As per the company, the top-line phase 2 data is on track which would be presented at Alzheimer’s Association International Conference at Los Angeles on July 17, 2019.
This randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety of two doses of Masupirdine (SUVN-502) in moderate Alzheimer’s disease patients who are taking both Aricept (donepezil) and Namenda (memantine).
With the completion of Phase 2, the company will a step closer in introducing new treatment option for people suffering from Alzheimer disease across the globe.
On Thursday, the stock of Suven Life Sciences opened at Rs. 253.75 per share. It surged by 6.3 per cent making intra-day high of Rs. 266.35 from the previous close of Rs. 250.60.